Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase IIb study of BPR-101 capsules combined with metronidazole for prevention of recurrent bacterial vaginosis
CTR20261307Phase 2Active
- Sponsor
- Chengdu Better Pharmaceutical
- Start
- Apr 2026
- Modality
- Small Molecules, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of BPR-101, metronidazole in bacterial vaginosis (BV), sponsored by Chengdu Better Pharmaceutical. Started Apr 2026; status: active.
02
Drugs
BPR-101metronidazole
03
Conditions
bacterial vaginosis (BV)
Beyond the preview
Go deeper on CTR20261307.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20261307.